Amarin | AMRN - Stammkapital





Stammkapital Veränderung Datum
AbbVie USD 1.77B 1.75B 2025-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amarin USD 20.81M 13K 2025-12
AstraZeneca USD 1.55B 44K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
DBV Technologies USD 235.6M 98.78M 2025-12
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Novartis USD 1.9B 7.38M 2026-06